Walgreens Boots Alliance, Inc. (WBA)
| Previous close | 17.93 |
| Open | 17.97 |
| Bid | 17.82 x 2400 |
| Ask | 17.84 x 100 |
| Day's range | 17.76 - 18.16 |
| 52-week range | 17.12 - 32.89 |
| Volume | |
| Avg. volume | 11,512,062 |
| Market cap | 15.386B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.00 |
| Earnings date | 25 June 2024 - 01 July 2024 |
| Forward dividend & yield | 1.00 (5.50%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | 20.32 |
ZacksWalgreens Boots Alliance, Inc. (WBA) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Walgreens (WBA). This makes it worthwhile to examine what the stock has in store.
Yahoo FinanceDow at 40,000: Why stocks still have 'plenty of room to run'
Wall Street pros say there's more room to grow with stock markets around record highs.
- Reuters
Walgreens launches own brand of opioid overdose reversal drug
U.S. pharmacy chain operator Walgreens Boots Alliance said on Wednesday it has launched its own brand of popular overdose reversal drug, naloxone, which would be available over-the-counter (OTC). The launch comes weeks after Walgreens' brand was approved by the U.S. Food and Drug Administration in April. Opioid abuse has plagued the United States for more than two decades and killed more than half a million Americans, with fentanyl and synthetic versions being a major culprit in recent years, according to government data.
